8-K current report · filed Jul 27, 2026

Gossamer Bio, Inc. (GOSS) 8-K Current Report: July 27, 2026

Item 1.01Item 2.02Item 7.01Item 8.01Item EX-99.1Item 1.02GOSS overview

Short answer

Gossamer Bio, Inc. (GOSS) filed an 8-K current report with the SEC on July 27, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 1.02 (Termination of a Material Definitive Agreement). Gossamer regains worldwide seralutinib rights and control across PAH, PH-ILD, and potential future indications.

Gossamer Bio, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Gossamer regains worldwide seralutinib rights and control across PAH, PH-ILD, and potential future indications
  • Chiesi to pay Gossamer $5 million within 10 days for outstanding development costs
  • Gossamer assumes success-based milestone payments and capped royalties on net sales of previously licensed products
  • Chiesi transfers related regulatory filings and intellectual property, with licenses revocable after uncured payment breaches
  • Agreement terminates the 2024 collaboration, preserves indemnities, and releases most legacy claims

Item 1.02 · Termination of a Material Definitive Agreement

  • License Agreement termination, as described in Item 1.01
  • Termination may alter Gossamer Bio’s rights, obligations and future economics under the agreement

Item 2.02 · Results of Operations and Financial Condition

  • Preliminary cash, cash equivalents and marketable securities of approximately $57.0 million as of June 30, 2026
  • Liquidity disclosure provides an early view of funding available for operations and clinical development
  • Unaudited figure remains subject to quarter-end closing adjustments

Item 7.01 · Regulation FD Disclosure

  • Gossamer Bio announced rights reacquisition and related license termination, signaling a material shift in its partnering strategy
  • Press release includes FDA regulatory and business updates relevant to development timelines and commercialization prospects
  • Full details are in Exhibit 99.1, covering the July 27, 2026 announcement

Item 8.01 · Other Events

  • Seralutinib NDA submission planned for September 2026 following FDA Type B meeting
  • FDA classified PROSERA statistical significance and treatment-effect magnitude as review issues, not filing issues
  • NDA strategy relies on Phase 3 PROSERA, Phase 2 TORREY, and supportive analyses
  • Potential FDA approval decision in Q3 2027 if the NDA is accepted for filing
  • FDA approvability remains uncertain pending review of the complete NDA

Item EX-99.1 · Exhibit EX-99.1

  • FDA feedback supports planned September 2026 NDA submission for seralutinib in PAH, with potential approval decision in Q3 2027 if accepted
  • FDA views PROSERA efficacy and statistical significance as review issues, not filing barriers, but approval remains uncertain
  • Worldwide seralutinib rights returned from Chiesi for a $5 million payment to Gossamer, with capped royalties and milestone payments owed
  • Convertible note exchange reduced debt by approximately $115.9 million, leaving approximately $18.9 million of 2027 Notes outstanding
  • Cash, cash equivalents and marketable securities totaled approximately $57 million at June 30, 2026; reverse split expected in or promptly after Q3 2026

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Gossamer Bio, Inc. 8-K filings

Get the next GOSS 8-K as it lands

Follow GOSS for push alerts, or ask the research agent what this filing means.